Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tetracycline is a broad-spectrum antibiotic of the tetracycline class produced by Streptomyces bacteria. It is used to treat a wide variety of bacterial infections including those affecting the respiratory tract (such as pneumonia), skin (including acne), eyes, lymphatic system, intestines, genitals and urinary tract. It is also indicated for infections spread by ticks and other vectors (e.g., plague and tularemia), as well as for anthrax and certain food poisonings in patients unable to take penicillin[1][2][3]. Tetracycline works by reversibly binding to the 30S ribosomal subunit of susceptible bacteria—blocking aminoacyl tRNA from binding at the A site—and thereby inhibiting protein synthesis; it can also bind to some extent to the 50S subunit[1][6]. This action prevents bacterial growth (bacteriostatic effect). The drug may also alter bacterial cytoplasmic membranes causing leakage of intracellular contents[1]. Tetracyclines are not effective against viral infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tetracycline.